Equities

Mabpharm Ltd

Mabpharm Ltd

Actions
  • Price (HKD)0.305
  • Today's Change0.00 / 0.00%
  • Shares traded40.00k
  • 1 Year change-37.11%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 03:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1734982
Total Receivables, Net444152
Total Inventory10210153
Prepaid expenses117.6513
Other current assets, total123.4248
Total current assets342201248
Property, plant & equipment, net687704561
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term1.812.408.82
Other long term assets3.003.413.00
Total assets1,035918900
LIABILITIES
Accounts payable101713
Accrued expenses596769
Notes payable/short-term debt000
Current portion long-term debt/capital leases125139.28
Other current liabilities, total12292144
Total current liabilities316188235
Total long term debt13511336
Total debt26012646
Deferred income tax------
Minority interest------
Other liabilities, total37921527
Total liabilities830517298
SHAREHOLDERS EQUITY
Common stock2.802.802.80
Additional paid-in capital1,4011,4011,401
Retained earnings (accumulated deficit)(1198)(1002)(801)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity205401602
Total liabilities & shareholders' equity1,035918900
Total common shares outstanding4,1244,1244,124
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.